Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL

May 31st 2020

Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

AMG 330 Shows Promise in Treating Relapsed/Refractory AML

May 30th 2020

Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia, with cytokine release syndrome as the most frequent and expected adverse event.

Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma

May 30th 2020

Treatment with pembrolizumab induced a 4.9-month progression-free survival benefit over brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma.

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas

May 30th 2020

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas.

Dr. Kuruvilla on Findings From the KEYNOTE-204 Trial in Hodgkin Lymphoma

May 29th 2020

John Kuruvilla, MD, FRCPC, discusses findings from the phase 3 KEYNOTE-204 trial in Hodgkin lymphoma.

Zanubrutinib Shows Clinical Activity, Tolerability in Waldenstrom Macroglobulinemia

May 29th 2020

Zanubrutinib demonstrated a higher complete response or very good partial response rate compared with ibrutinib in patients with Waldenström macroglobulinemia, although the findings were not found to be statistically significant.

Dr. Brammer on Data With Inotuzumab Ozogamicin in ALL

May 27th 2020

Jonathan E. Brammer, MD, discusses data that have been reported with inotuzumab ozogamicin (Besponsa) in acute lymphoblastic leukemia (ALL).

Dr. Mims on the Beat AML Master Trial in AML

May 27th 2020

Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).

Dr. Kaplan on Research With Bispecific Monoclonal Antibodies in Follicular Lymphoma

May 27th 2020

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Dr. Altomare on Investigational Agents in ITP

May 23rd 2020

Ivy P. Altomare, MD, discusses investigational agents in immune thrombocytopenia.

Dr. Radich on Measuring MRD in Hematologic Malignancies

May 23rd 2020

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.

Novel Treatments Expand Second-Line Options in ITP

May 22nd 2020

Ivy P. Altomare, MD, the prognosis of patients with immune thrombocythemia, available treatment options, and emerging treatment modalities on the horizon.

Tisagenlecleucel Enhances Health-Related QoL in Relapsed/Refractory DLBCL

May 22nd 2020

Tisagenlecleucel led to clinically meaningful and durable improvements in health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma who achieved a complete or partial response to the CD19-directed CAR T-cell therapy in the phase 2 JULIET trial.

Tafasitamab/Lenalidomide Combo Application Fast-Tracked in Europe

May 22nd 2020

The European Medicines Agency has validated a Marketing Authorization for the combination of tafasitamab and lenalidomide, followed by single-agent lenalidomide, for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma, including DLBCL arising from low-grade lymphoma, who are ineligible for autologous stem cell transplant.

Concurrent Cladribine/Rituximab Enhances MRD-Free Complete Responses in Hairy Cell Leukemia

May 22nd 2020

Concurrent frontline therapy with cladribine and rituximab led to a significant improvement in minimal residual disease–free complete responses versus cladribine followed by delayed rituximab in patients with hairy cell leukemia.

Dr. Smith on Unmet Clinical Needs in Indolent Lymphomas

May 22nd 2020

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Belumosudil Impresses in cGVHD, FDA Submission Started

May 21st 2020

Belumosudil (KD025) continued to show high levels of clinical activity in patients with previously treated chronic graft-versus-host disease.

ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 21st 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Schroeder on the Importance of JAK Inhibition in GVHD

May 19th 2020

Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).